Virtual Enhanced Lifestyle for Metabolic Syndrome (ELM) Proof-of-Concept Study

NCT ID: NCT04637477

Last Updated: 2021-09-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-01
• Study Completion Date: 2021-08-25

Brief Summary

This is a proof-of-concept study of a virtual version of a lifestyle intervention aimed at reducing cardiometabolic risk in patients with the Metabolic Syndrome (MetS). The aim is to recruit 12 patients at high risk for coronavirus infection based upon a diagnosis of obesity and the MetS, conduct a 12-week virtual version of the in-person intervention, and explore efficacy using clinically significant pre-specified targets for weight, diet, physical activity, stress, and markers of inflammation. In addition, the investigators will explore safety, fidelity, feasibility, and acceptability.

Conditions

Metabolic Syndrome; Obesity

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Virtual ELM

Group Type: EXPERIMENTAL

Virtual ELM

Intervention Type: BEHAVIORAL

Participants will attend 1.5-hour virtual group-based sessions for 12 weeks. The program includes physical activity, cooking demonstrations, and group discussions. All sessions are led by a registered dietitian and health psychologist.

Interventions

Virtual ELM

Participants will attend 1.5-hour virtual group-based sessions for 12 weeks. The program includes physical activity, cooking demonstrations, and group discussions. All sessions are led by a registered dietitian and health psychologist.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

1. Men and women with components of the metabolic syndrome, defined by an adapted version of the Joint Interim Statement of the IDF, NHLBI, AHA, WHF, IAS, IASO (Alberti, 2009). Surrogates for waist circumference and fasting glucose were selected to help identify prospective participants using medical records. Participants must have ≥ 2 of the following five criteria to participate in the study:

• Waist circumference based on AHA/NHLBI (ATP III) cut points of ≥ 102 cm for men and ≥ 88 cm for women or BMI≥30
• Triglycerides ≥150 mg/dL or treatment for elevated triglycerides
• HDL cholesterol <40 mg/dL in men or <50 mg/dL in women, or treatment for low HDL
• Systolic blood pressure ≥130 m Hg, diastolic blood pressure ≥85 mm Hg, or treatment for hypertension
• Fasting plasma glucose 100-125 mg/dL (range inclusive), or on metformin, or HbA1c between 5.7 and 6.4.

2. Age 18 years or older

3. Highly motivated to make lifestyle changes as a way to manage the MetS.

Exclusion Criteria

1. Individuals who report being unable to walk 2 consecutive blocks without assistance are ineligible. Additionally, individuals who endorse pain, tightness, or pressure in their chest during physical activity (on question 1 of the EASY screener) or current dizziness or lightheadedness (on question 2 of the EASY screener) may not be randomized without providing documentation in writing from their physician indicating that they have been cleared for participation in the trial.

2. Unwilling, unable, or not ready to make the lifestyle changes prescribed in ELM

3. BMI <27 or > 40

4. Weight > 397 lbs. The Fitbit Aria scale, utilized in the intervention, measures up to 397 lbs.

5. Unable to consistently attend group classes at the anticipated time due to schedule conflicts or other reasons.

6. Unable or unwilling to give an informed consent or communicate with study staff.

7. Unable or unwilling to complete accelerometer data collection.

8. Does not have reliable access to the internet.

9. Does not have a smart phone. Must be willing to download the Fitbit app on their smart phone.

10. Not fluent in English

11. Current diagnosis of type 1 or type 2 diabetes, on any diabetes medications except metformin, or has a screening A1c ≥6.5

12. Inpatient treatment for a psychiatric condition within the past 6 months, or currently receiving treatment for schizophrenia or other serious psychiatric illness

13. Probable major depression, defined as a PHQ-8 score ≥10

14. Pregnant women, planning a pregnancy in the next 2 months, given birth in the last 6 months, or currently breastfeeding

15. ≥ 30 total days of oral corticosteroid use within the last year, history of solid organ transplant, or history of stem cell transplant

16. Problematic use of alcohol and/or recreational drugs, defined as ASSIST screening score of ≥27.

17. Self-reported or known history of an eating disorder (e.g., binging and purging) in the past 5 years

18. Use of weight loss medications (Qsymia, orlistat, phentermine, Saxenda, etc.) in the last 3 months, or unwilling to abstain from taking weight loss medications or supplements during the trial

19. History of bowel resection surgery or bariatric surgery

20. Any medical condition known to influence the etiology of MetS as judged by the study physician (e.g., uncontrolled hypothyroidism, endocrine hypertension, etc)

21. History of major cardiovascular illness, including: a) stroke; b) myocardial infarction; c) congestive heart failure requiring hospitalization, or greater than NYHA heart failure class I; d) uncontrolled hypertension (SBP>180 or DBP > 109); e) unstable angina or an active prescription for sublingual nitroglycerin; or f) other major cardiovascular illness which the site PI determines could limit ability to participate in the trial. Individuals screened for participation, whose screening systolic blood pressure is ≥160 and ≤179, or whose screening diastolic blood pressure is ≥100 and ≤109 are considered to have MODERATE, or Stage 3 Hypertension. If they otherwise qualify and wish to participate in ELM, they will be referred to their physician for clearance prior to randomization.

22. Cognitive impairment

23. Visual or hearing impairment

24. Currently taking or expecting to take any of the following exclusionary medications:

1. Antiretroviral therapy (e.g., HAART)

2. Weight loss medications (as in #14)

3. Medications known to significantly influence weight or metabolic outcomes

4. Diabetes drugs other than metformin (as in #7)

25. Receiving dialysis

26. Cancer treatment within the last 6 months, excluding chemoprophylaxis or treatment for non-melanoma skin cancer

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Missouri, Kansas City

OTHER

Sponsor Role: collaborator

University of Colorado, Denver

OTHER

Sponsor Role: collaborator

Geisinger Clinic

OTHER

Sponsor Role: collaborator

Rochester Institute of Technology

OTHER

Sponsor Role: collaborator

Rush University Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lynda Powell, PhD

Role: PRINCIPAL_INVESTIGATOR

Rush University Medical Center

Locations

Rush University Medical Center

Chicago, Illinois, United States

University of Missouri-Kansas City School of Medicine

Kansas City, Missouri, United States

Countries

United States

Other Identifiers

20061108

Identifier Type: -

Identifier Source: org_study_id